Clinical trial · Observational
One Million Cancer Treatment Months
Development of an Artificial Intelligence-based Incident Prediction Algorithm to Improve Cancer Patient Care and Patient Safety
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The OMCAT Register aims to provide learning databases in cancer comprising both PRO data using PRO-React and "ground truth" (outcome data verified by the physician during patient examinations). Intelligent learning and knowledge engineering procedures will utilize this PRO data to provide high-quality event prediction algorithms. The ground-truth data enables so-called "supervised learning" techniques of artificial intelligence, because predicted events can be verified with a high level of certainty from ground-truth data.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CANKADO PRO-React Onco | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (8)
- measure
- Health Status
- timeFrame
- 6 months
- description
- Using the EuroQol-visual analogue scale, abbreviated as EQ-VAS Scale, containing values between 100 (best imaginable health) and 0 (worst imaginable health), (answered by patients)
- measure
- Complaints/Symptoms
- timeFrame
- 6 months
- description
- Assessed using a question set aligned with the PRO-CTCAE and CTCAE (answered by patients)
- measure
- Presence or Absence of SAEs
- timeFrame
- 6 months
- description
- yes/no (answered by physician)
- measure
- Presence or Absence of dosis reductions
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed informed consent * Age ≥ 18 years * Diagnosed with cancer * Prescribed CANKADO PRO-React Onco Exclusion Criteria: * Lack of consent to study participation or lack of patient's ability to consent * Enrolled in this trial within a further treatment
References
Publications (0)
Data not yet available